By using, you agree to our terms and use of cookies to enhance your experience.

Type 2 diabetes glycaemic control guideline published

By Editor
8th December 2017
Clinical guidance, Type 2 diabetes

Guidelines on glycaemic control in people with type 2 diabetes have been published by an organisation which aims to improve the quality of healthcare for people in Scotland.

The Scottish Intercollegiate Guidelines Network (SIGN) develops and distributes national clinical guideline national clinical guidelines containing recommendations for effective practice based on current evidence.

The recently published document, SIGN 154: Pharmacological Management of Glycaemic Control in People with Type 2 Diabetes, provides evidence-based recommendations and best practice guidance on optimal targets for glucose control for the prevention of microvascular and microvascular complications and the risks and benefits of the principal therapeutic classes of glucose-lowering agents and insulins currently available for those who require measures beyond diet and exercise to achieve glucose targets.

An updated algorithm to guide the choice of first, second and third-line glucose-lowering agent, which incorporates the summarised evidence and the clinical experience of the guideline development group, has also been included.

They have been specifically developed for healthcare professionals involved in the management of people with diabetes, including diabetologists, diabetes specialist nurses, general practitioners, pharmacists and practice nurses.

They will also be of interest to people with diabetes and their carers, voluntary organisations and policy makers. The target users for SIGN 116 also includes those who interact with people with diabetes outside of the NHS, such as parents and teachers.

Some of the content in the new guideline was originally published in section 6 of SIGN 116: Management of diabetes.

However, because of significant volume of new evidence relating to pharmacological treatment of glucose lowering in people with type 2 diabetes that has been published since SIGN 116 was issued in 2010, and to support the publication of a revised Scottish Diabetes Prescribing Strategy, the update has now been published as a stand-alone guideline.

Founded in 1993, SIGN collaborate with a network of clinicians, other health and social care professionals, patient organisations and individuals to develop evidence-based guidelines.

Its guidelines are based on a systematic review of the scientific literature and are aimed at aiding the translation of new knowledge into action.

Comments (0)

Register an account or login to comment